A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia

Trial Profile

A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2007

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Sponsors Takeda Europe Research & Development Centre
  • Most Recent Events

    • 01 Sep 2007 Results reported in an abstract from the proceedings of the ESC Congress 2007: Annual Congress of the European Society of Cardiology, 01 Sep 2007.
    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top